P1117: GLOFITAMAB PLUS R-CHOP OR POLATUZUMAB VEDOTIN-R-CHP IS DELIVERABLE AND YIELDS HIGH OVERALL RESPONSE IN PATIENTS <=65 YEARS OF AGE WITH HIGH-RISK DLBCL OR HGBL: INTERIM ANALYSIS OF THE COALITION STUDY

Lignende værker

• Cost-effectiveness of polatuzumab vedotin plus chemoimmunotherapy for untreated diffuse large B-cell lymphoma in China
  af: Mengya Li, et al.
  Udgivet: (2025-08-01)
• First-line Polatuzumab vedotin plus R-CHP in primary mediastinal B-cell lymphoma: A real-world study bridging the gap of the POLARIX trial
  af: Xue Yang, et al.
  Udgivet: (2026-04-01)
• A Comprehensive Review of Polatuzumab vedotin: Mechanisms, Clinical Applications, and Future Prospects
  af: Divya Shanthi, et al.
  Udgivet: (2024-03-01)
• Advances in Polatuzumab Vedotin-PIIQ Therapy: A Review of Treatment Efficacy in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma
  af: Abdur Raqib M, et al.
  Udgivet: (2023-10-01)
• Polatuzumab Vedotin Induced CD20 Upregulation Contributes to the Efficacy of Mosunetuzumab in Combination With Polatuzumab Vedotin in Diffuse Large B‐Cell Lymphoma Preclinical Models
  af: Natsumi Kawasaki, et al.
  Udgivet: (2025-10-01)